Biotech entity
Every one of those 1 sits in a single category, clinical-trial. Hagens Berman Sobol Shapiro LLP is most often covered alongside ERAS-0015, which appears in 1 of these 1 story. The tracked stories average 2 original sources each. Hagens Berman Sobol Shapiro LLP appears in 1 tracked Biotech story from June 16, 2026.
Last mentioned: Jun 16, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, clinical-trial. Hagens Berman Sobol Shapiro LLP is most often covered alongside ERAS-0015, which appears in 1 of these 1 story. The tracked stories average 2 original sources each. Hagens Berman Sobol Shapiro LLP appears in 1 tracked Biotech story from June 16, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 2 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Hagens Berman Sobol Shapiro LLP. Shared-story counts are live from our verified record — not editorial picks.
Revolution Medicines' patent infringement claim and a patient death have derailed Erasca's lead candidate, cutting its valuation by $2.8B. The biotech now faces a class action over alleged misrepresentations.
Source: Globenewswire_fr · Benzinga
Hagens Berman Sobol Shapiro LLP is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
